Walt F Lima
Overview
Explore the profile of Walt F Lima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prakash T, Lima W, Murray H, Li W, Kinberger G, Chappell A, et al.
Nucleic Acids Res
. 2017 May;
45(11):6994.
PMID: 28472515
No abstract available.
2.
Donner A, Wancewicz E, Murray H, Greenlee S, Post N, Bell M, et al.
Nucleic Acid Ther
. 2017 Apr;
27(4):209-220.
PMID: 28448194
Phosphorothioate (PS) modified antisense oligonucleotides (ASOs) have progressed rapidly in the clinic for treating a variety of disease indications. We previously demonstrated that the activity of PS ASOs in the...
3.
Schirle N, Kinberger G, Murray H, Lima W, Prakash T, MacRae I
J Am Chem Soc
. 2016 Jul;
138(28):8694-7.
PMID: 27380263
Incorporation of chemical modifications into small interfering RNAs (siRNAs) increases their metabolic stability and improves their tissue distribution. However, how these modifications impact interactions with Argonaute-2 (Ago2), the molecular target...
4.
Prakash T, Kinberger G, Murray H, Chappell A, Riney S, Graham M, et al.
Bioorg Med Chem Lett
. 2016 May;
26(12):2817-2820.
PMID: 27161280
Chemical modifications are essential to improve metabolic stability and pharmacokinetic properties of siRNA to enable their systemic delivery. We investigated the effect of combing the phosphorothioate (PS) modification with metabolically...
5.
Lima W, Murray H, Damle S, Hart C, Hung G, De Hoyos C, et al.
Nucleic Acids Res
. 2016 May;
44(11):5299-312.
PMID: 27131367
Viable constitutive and tamoxifen inducible liver-specific RNase H1 knockout mice that expressed no RNase H1 activity in hepatocytes showed increased R-loop levels and reduced mitochondrial encoded DNA and mRNA levels,...
6.
Lima W, De Hoyos C, Liang X, Crooke S
Nucleic Acids Res
. 2016 Feb;
44(7):3351-63.
PMID: 26843429
DNA-based antisense oligonucleotides (ASOs) elicit cleavage of the targeted RNA by the endoribonuclease RNase H1, whereas siRNAs mediate cleavage through the RNAi pathway. To determine the fates of the cleaved...
7.
Prakash T, Lima W, Murray H, Li W, Kinberger G, Chappell A, et al.
Nucleic Acids Res
. 2015 Mar;
43(6):2993-3011.
PMID: 25753666
The ss-siRNA activity in vivo requires a metabolically stable 5'-phosphate analog. In this report we used crystal structure of the 5'-phosphate binding pocket of Ago-2 bound with guide strand to...
8.
Wan W, Migawa M, Vasquez G, Murray H, Nichols J, Gaus H, et al.
Nucleic Acids Res
. 2014 Nov;
42(22):13456-68.
PMID: 25398895
Bicyclic oxazaphospholidine monomers were used to prepare a series of phosphorothioate (PS)-modified gapmer antisense oligonucleotides (ASOs) with control of the chirality of each of the PS linkages within the 10-base...
9.
Lima W, Vickers T, Nichols J, Li C, Crooke S
PLoS One
. 2014 Jul;
9(7):e101752.
PMID: 25072142
To better understand the factors that influence the activity and specificity of antisense oligonucleotides (ASOs), we designed a minigene encoding superoxide dismutase 1 (SOD-1) and cloned the minigene into vectors...
10.
Prakash T, Graham M, Yu J, Carty R, Low A, Chappell A, et al.
Nucleic Acids Res
. 2014 Jul;
42(13):8796-807.
PMID: 24992960
Triantennary N-acetyl galactosamine (GalNAc, GN3: ), a high-affinity ligand for the hepatocyte-specific asialoglycoprotein receptor (ASGPR), enhances the potency of second-generation gapmer antisense oligonucleotides (ASOs) 6-10-fold in mouse liver. When combined...